Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22343501 | 1.00 | PDPK1 (0.39) | PDPK1MKNK2USP30ALDH1A1LMNA | |
| SCHEMBL22325345 | 0.94 | PDPK1 (0.36) | PDPK1ATR | |
| SCHEMBL22343547 | 0.88 | PDPK1 (0.38) | PDPK1 | |
| SCHEMBL29657140 | 0.88 | PDPK1 (0.38) | PDPK1 | |
| SCHEMBL17362938 | 0.83 | PDPK1 (0.40) | PDPK1MKNK2USP30ALDH1A1LMNA | |
| SCHEMBL22325327 | 0.83 | PDPK1 (0.35) | PDPK1 | |
| SCHEMBL22343502 | 0.78 | PDPK1 (0.37) | PDPK1 | |
| SCHEMBL17362870 | 0.77 | PDPK1 (0.40) | PDPK1MKNK2USP30ALDH1A1LMNA | |
| SCHEMBL30381577 | 0.77 | PDPK1 (0.40) | PDPK1MKNK2USP30ALDH1A1LMNA | |
| SCHEMBL17362914 | 0.77 | MKNK2 (0.41) | PDPK1MKNK2USP30ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325707-B2 | Process for preparing enantiomerically enriched JAK inhibitors | SUN PHARMACEUTICAL INDUSTRIES, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240368166-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240300963-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2024-09-12 | — | — | US | disclosed |
| US-20220306636-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2022-09-29 | — | — | US | disclosed |
| US-20220213105-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12325707-B2 | Process for preparing enantiomerically enriched JAK inhibitors | JAK1, JAK2, JAK3 | PDPK1 121/4885MKNK2 467/4885USP30 843/4885 |
| US-20220213105-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | PDPK1 121/4885MKNK2 467/4885USP30 843/4885 |
| US-20240300963-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | PDPK1 121/4885MKNK2 467/4885USP30 843/4885 |
| US-20240368166-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | PDPK1 121/4885MKNK2 467/4885USP30 843/4885 |
| US-20220306636-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | JAK1, JAK2, JAK3 | PDPK1 121/4885MKNK2 467/4885USP30 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.